143 related articles for article (PubMed ID: 23613284)
1. Multiple neurofibromas as the presenting feature of familial atypical multiple malignant melanoma (FAMMM) syndrome.
Vanneste R; Smith E; Graham G
Am J Med Genet A; 2013 Jun; 161A(6):1425-31. PubMed ID: 23613284
[TBL] [Abstract][Full Text] [Related]
2. CDKN2A mutations with p14 loss predisposing to multiple nerve sheath tumours, melanoma, dysplastic naevi and internal malignancies: a case series and review of the literature.
Sargen MR; Merrill SL; Chu EY; Nathanson KL
Br J Dermatol; 2016 Oct; 175(4):785-9. PubMed ID: 26876133
[TBL] [Abstract][Full Text] [Related]
3. Screening of germline mutations in the CDKN2A and CDKN2B genes in Swedish families with hereditary cutaneous melanoma.
Platz A; Hansson J; Månsson-Brahme E; Lagerlof B; Linder S; Lundqvist E; Sevigny P; Inganäs M; Ringborg U
J Natl Cancer Inst; 1997 May; 89(10):697-702. PubMed ID: 9168184
[TBL] [Abstract][Full Text] [Related]
4. [From gene to disease; from p16 to melanoma].
Gruis NA; Bergman W
Ned Tijdschr Geneeskd; 2000 Oct; 144(44):2100-2. PubMed ID: 11103670
[TBL] [Abstract][Full Text] [Related]
5. CDKN2A mutation in a non-FAMMM kindred with cancers at multiple sites results in a functionally abnormal protein.
Sun S; Pollock PM; Liu L; Karimi S; Jothy S; Milner BJ; Renwick A; Lassam NJ; Hayward NK; Hogg D; Narod SA; Foulkes WD
Int J Cancer; 1997 Nov; 73(4):531-6. PubMed ID: 9389568
[TBL] [Abstract][Full Text] [Related]
6. CDKN2A point mutations D153spl(c.457G>T) and IVS2+1G>T result in aberrant splice products affecting both p16INK4a and p14ARF.
Rutter JL; Goldstein AM; Dávila MR; Tucker MA; Struewing JP
Oncogene; 2003 Jul; 22(28):4444-8. PubMed ID: 12853981
[TBL] [Abstract][Full Text] [Related]
7. Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma-pancreatic carcinoma-prone families: the familial atypical mole melanoma-pancreatic carcinoma syndrome.
Lynch HT; Brand RE; Hogg D; Deters CA; Fusaro RM; Lynch JF; Liu L; Knezetic J; Lassam NJ; Goggins M; Kern S
Cancer; 2002 Jan; 94(1):84-96. PubMed ID: 11815963
[TBL] [Abstract][Full Text] [Related]
8. Genetic counselling and high-penetrance susceptibility gene analysis reveal the novel CDKN2A p.D84V (c.251A>T) mutation in melanoma-prone families from Italy.
Borroni RG; Manganoni AM; Grassi S; Grasso M; Diegoli M; Giorgianni C; Favalli V; Pavoni L; Cespa M; Arbustini E
Melanoma Res; 2017 Apr; 27(2):97-103. PubMed ID: 28060055
[TBL] [Abstract][Full Text] [Related]
9. Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden).
Vasen HF; Gruis NA; Frants RR; van Der Velden PA; Hille ET; Bergman W
Int J Cancer; 2000 Sep; 87(6):809-11. PubMed ID: 10956390
[TBL] [Abstract][Full Text] [Related]
10. FAMMM syndrome: pathogenesis and management.
Czajkowski R; Placek W; Drewa G; Czajkowska A; Uchańska G
Dermatol Surg; 2004 Feb; 30(2 Pt 2):291-6. PubMed ID: 14871223
[TBL] [Abstract][Full Text] [Related]
11. Pancreatic carcinoma surveillance in patients with familial melanoma.
Parker JF; Florell SR; Alexander A; DiSario JA; Shami PJ; Leachman SA
Arch Dermatol; 2003 Aug; 139(8):1019-25. PubMed ID: 12925390
[TBL] [Abstract][Full Text] [Related]
12. CDKN2A germline splicing mutation affecting both p16(ink4) and p14(arf) RNA processing in a melanoma/neurofibroma kindred.
Petronzelli F; Sollima D; Coppola G; Martini-Neri ME; Neri G; Genuardi M
Genes Chromosomes Cancer; 2001 Aug; 31(4):398-401. PubMed ID: 11433531
[TBL] [Abstract][Full Text] [Related]
13. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families.
Borg A; Sandberg T; Nilsson K; Johannsson O; Klinker M; Måsbäck A; Westerdahl J; Olsson H; Ingvar C
J Natl Cancer Inst; 2000 Aug; 92(15):1260-6. PubMed ID: 10922411
[TBL] [Abstract][Full Text] [Related]
14. Immunophenotypic p14 and p16 correlations with CDKN2A mutations in primary multiple and familial melanoma: An observational study.
Boşoteanu LA; Gheorghe E; Aşchie M; Cozaru GC; Deacu M; Orășanu CI; Boşoteanu M
Medicine (Baltimore); 2023 Dec; 102(51):e36756. PubMed ID: 38134090
[TBL] [Abstract][Full Text] [Related]
15. Genomic rearrangements of the CDKN2A locus are infrequent in Italian malignant melanoma families without evidence of CDKN2A/CDK4 point mutations.
Vignoli M; Scaini MC; Ghiorzo P; Sestini R; Bruno W; Menin C; Gensini F; Piazzini M; Testori A; Manoukian S; Orlando C; D'Andrea E; Bianchi-Scarrà G; Genuardi M
Melanoma Res; 2008 Dec; 18(6):431-7. PubMed ID: 19011513
[TBL] [Abstract][Full Text] [Related]
16. CDKN2A variants in a population-based sample of Queensland families with melanoma.
Aitken J; Welch J; Duffy D; Milligan A; Green A; Martin N; Hayward N
J Natl Cancer Inst; 1999 Mar; 91(5):446-52. PubMed ID: 10070944
[TBL] [Abstract][Full Text] [Related]
17. CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas.
Hashemi J; Platz A; Ueno T; Stierner U; Ringborg U; Hansson J
Cancer Res; 2000 Dec; 60(24):6864-7. PubMed ID: 11156381
[TBL] [Abstract][Full Text] [Related]
18. CDKN2A mutations in Spanish cutaneous malignant melanoma families and patients with multiple melanomas and other neoplasia.
Ruiz A; Puig S; Malvehy J; Lázaro C; Lynch M; Gimenez-Arnau AM; Puig L; Sánchez-Conejo J; Estivill X; Castel T
J Med Genet; 1999 Jun; 36(6):490-3. PubMed ID: 10874641
[TBL] [Abstract][Full Text] [Related]
19. Identification of modifier genes for cutaneous malignant melanoma in melanoma-prone families with and without CDKN2A mutations.
Yang XR; Pfeiffer RM; Wheeler W; Yeager M; Chanock S; Tucker MA; Goldstein AM
Int J Cancer; 2009 Dec; 125(12):2912-7. PubMed ID: 19626699
[TBL] [Abstract][Full Text] [Related]
20. Population-based prevalence of CDKN2A mutations in Utah melanoma families.
Eliason MJ; Larson AA; Florell SR; Zone JJ; Cannon-Albright LA; Samlowski WE; Leachman SA
J Invest Dermatol; 2006 Mar; 126(3):660-6. PubMed ID: 16397522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
